Prostaglandin ep1 receptor

Abstract

(1) A novel polypeptide prostaglandin E receptor, (2) a cDNA encoding the polypeptide and a fragment selectively hybridized to the sequence of the cDNA, (3) a replication or expression vector carrying the DNA, (4) a host cell transformed with the replication or the expression vector, (5) a method for producing the polypeptide which comprises culturing the host cells, (6) a monoclonal or polyclonal antibody against the polypeptide, (7) a pharmaceutical composition containing the polypeptide or the antibody, in association with pharmaceutically acceptable excipient and/or antibody, (8) a screening method for a compound having agonistic or antagonistic activity against EP1, comprising using the polypeptide or the host cell. The polypeptide of the present invention can be used for treating diseases, which is caused by over production of PGE 2 , such as pain, fever and pollakiuria.

1 . A polypeptide comprising the amino acid sequence shown in SEQ ID NO:1.  
     
     
         2 . A cDNA encoding the polypeptide according to  claim 1 .  
     
     
         3 . A DNA according to  claim 2 , comprising the nucleotide sequence shown in SEQ ID NO:2, or a fragment DNA selectively hybridized to the sequence.  
     
     
         4 . A replication or expression vector carrying the DNA according to claims  2  or  3 .  
     
     
         5 . A host cell transformed with the replication or expression vector according to  claim 4 .  
     
     
         6 . A method for producing the polypeptide according to  claim 1  which comprises culturing the host cell according to  claim 5  under a condition effective to express the polypeptide according to  claim 1 .  
     
     
         7 . A monoclonal or polyclonal antibody against the polypeptide according to  claim 1 .  
     
     
         8 . A pharmaceutical composition containing the polypeptide according to  claim 1  or the antibody according to  claim 7 , in association with pharmaceutically acceptable excipient and/or antibody.  
     
     
         9 . A method for screening a compound having agonistic or antagonistic activity against EP1, comprising using the polypeptide according to  claim 1 .  
     
     
         10 . A method for screening a compound having agonistic or antagonistic activity against EP1, comprising using the host cell according to  claim 5.